GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (WBO:MDG1) » Definitions » EV-to-FCF

Medigene AG (WBO:MDG1) EV-to-FCF : -1.66 (As of May. 05, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Medigene AG EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Medigene AG's Enterprise Value is €26.24 Mil. Medigene AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-15.78 Mil. Therefore, Medigene AG's EV-to-FCF for today is -1.66.

The historical rank and industry rank for Medigene AG's EV-to-FCF or its related term are showing as below:

WBO:MDG1' s EV-to-FCF Range Over the Past 10 Years
Min: -43.19   Med: -4.18   Max: 2.39
Current: -1.66

During the past 13 years, the highest EV-to-FCF of Medigene AG was 2.39. The lowest was -43.19. And the median was -4.18.

WBO:MDG1's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 4.57 vs WBO:MDG1: -1.66

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Medigene AG's stock price is €1.515. Medigene AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.627. Therefore, Medigene AG's PE Ratio for today is At Loss.


Medigene AG EV-to-FCF Historical Data

The historical data trend for Medigene AG's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG EV-to-FCF Chart

Medigene AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.78 -2.44 -4.78 1.83 -1.50

Medigene AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.78 - 1.83 - -1.50

Competitive Comparison of Medigene AG's EV-to-FCF

For the Biotechnology subindustry, Medigene AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigene AG's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigene AG's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Medigene AG's EV-to-FCF falls into.



Medigene AG EV-to-FCF Calculation

Medigene AG's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=26.239/-15.783
=-1.66

Medigene AG's current Enterprise Value is €26.24 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medigene AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-15.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medigene AG  (WBO:MDG1) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Medigene AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.515/-0.627
=At Loss

Medigene AG's share price for today is €1.515.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medigene AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.627.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Medigene AG EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Medigene AG's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigene AG (WBO:MDG1) Business Description

Traded in Other Exchanges
Address
Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.

Medigene AG (WBO:MDG1) Headlines

No Headlines